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Safety and long-term efficacy of
thoracoscopic Epicardial ablation in
patients with paroxysmal atrial fibrillation: a
retrospective study
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Abstract
Background: The aim of this study is to report the long-term efficacy and safety of thoracoscopic epicardial left
atrial ablation (TELA) in patients with paroxysmal atrial fibrillation (AF).
Methods: This was a retrospective review of medical records. We included all patients diagnosed with paroxysmal
AF who underwent TELA at our institution between 04/2011 and 06/2017. TELA included pulmonary vein isolation,
LA dome lesions and LA appendage exclusion. All (n = 55) patients received an implantable loop recorder (ILR), 30
days post-operatively. Antiarrhythmic and anticoagulation therapy were discontinued at 90 and 180 days
postoperatively, respectively, if patients were free of AF recurrence. Failure was defined as ≥two minutes of
continuous AF, or atrial tachycardia.
Results: Fifty-five patients (78% males, mean age = 61.6 years) qualified for the study. The average duration in AF
was 3.64 +/− 3.4 years, mean CHA2DS2-VASc Score was 2.0 +/− 1.6. The procedure was attempted in 57 patients
and completed successfully in 55 (96.5%). Two patients experienced a minor pulmonary vein bleed that was
managed conservatively. Post procedure, one patient experienced pulmonary edema, another experienced a
pneumothorax requiring a chest tube and another experienced acute respiratory distress syndrome resulting in
longer hospitalization. Otherwise, there were no major procedural complications. Success rates were 89.1% (n = 49/
55), 85.5% (n = 47/55) and 76.9% (n = 40/52) at 6, 12 and 24 months, respectively. In the multivariate cox-
proportional hazard model, survival at the mean of covariates was 86 and 74% at 12 and 24 months, respectively.
Conclusion: In this single center experience, TELA was a safe and efficacious procedure for patients with
paroxysmal AF.
Keywords: Atrial fibrillation, Arrhythmia, Thoracoscopic, Epicardial ablation, Anticoagulation, Pulmonary vein
isolation, Implantable loop recorder
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Introduction
Atrial fibrillation (AF) is the most common cardiac
arrhythmia with several adverse consequences related to
a reduction in cardiac output, and to ischemic cerebro-
vascular accidents or peripheral embolization due to
atrial and atrial appendage thrombus formation [1].
Though AF is an independent risk factor of mortality, a
causal relationship has not been established [2]. An at-
tempt to maintain sinus rhythm is made in patients
based on the presence or absence of symptoms and evi-
dence that myocardial function is being compromised
[3]. The most commonly performed invasive procedure
used to maintain sinus rhythm is catheter ablation. The
efficacy of catheter ablation may vary considerably, de-
pending on the strategy and technology used and the
stage of the electroanatomic disease [4]. In 2006, Wolf
et al. [5] described a video-assisted thoracoscopic surgi-
cal ablation consisting of pulmonary vein isolation (PVI)
from the epicardial side with a bipolar radiofrequency
clamp, ablation of ganglia over the left atrial (LA) sur-
face, and excision of the LA appendage. This procedure
is performed with video-assisted thoracoscopic access to
the epicardial space through small, either right-sided or
bilateral thoracic incisions and primarily focuses on PVI.
The pulmonary veins are electrically isolated with a bi-
polar radiofrequency ablation clamp or suction assisted
unidirectional device. Additional ablation of ganglia or
the left atrium can also be performed epicardially. As a
stand-alone procedure, thoracoscopic epicardial left
atrial ablation (TELA) is limited to PVI, either as a box
or islands around each side. An endocardial approach is
necessary to connect any lesion to either the mitral or
tricuspid valves. Initial efficacy of TELA has been re-
ported to be > 90% in selected populations [6, 7]. Similar
to traditional catheter ablation, there is no evidence that
survival is improved with TELA [8, 9]. The need for
long-term anticoagulation after surgical ablation of AF
remains unclear. TELA may reduce stroke risk and
therefore the need for long-term anticoagulation. HRS/
EHRA/ECAS/APHRS/SOLAECE expert consensus state-
ment on catheter and surgical ablation of atrial fibrilla-
tion recommends stand-alone surgical ablation as a
reasonable option for persistent and long-standing pa-
tients who have failed one or more attempts at catheter
ablation who prefer a surgical approach after review of
safety and efficacy of options. For paroxysmal AF, it may
also be considered after one or more catheter attempts
[10]. The Society of Thoracic Surgeons 2017 Clinical
Practice Guidelines for the Surgical Treatment of Atrial
Fibrillation recommends stand-alone surgical ablation
for symptomatic AF without structural heart disease in
patients who have failed a class I or III antiarrhythmic
medication or catheter-based therapy [11]. The aim of
this retrospective study was to assess the long-term
efficacy and safety of TELA as a stand-alone procedure
in patients with paroxysmal atrial fibrillation.
Methods
This study was a retrospective review of medical records.
We included all patients diagnosed with paroxysmal AF
who underwent TELA at our institution between 04/
2011 and 06/2017. The patients did not tolerate or have
failed antiarrhythmic drugs. At that time interval, there
was no dedicated electrophysiology service at the hos-
pital. The surgeon (JJ), explained the TELA procedure to
patients. Patients were also informed that catheter-based
PVI was the gold standard for ablation procedures, and
they were offered a referral to a center where catheter-
based ablation can be performed. Patients who denied a
referral and opted to undergo TELA were included in
this study.
Exclusion criteria for the procedure were previous
lung lobectomy, or pericardial surgery and a body mass
index above 35 kg/m2. Patients’ anticoagulation drugs
were held prior to the procedure and resumed the night
following the procedure. The procedure included PVI,
ganglia mapping and ablation, left atrial dome lesions,
superior vena cava lesion, and left atrial appendage ex-
clusion. Under general anesthesia, three 10mm ports
sites were created. The right side was performed first.
The pericardium was opened and retracted posteriorly.
Using the AtriCure® Transpolar Pen, the autonomic gan-
glia were mapped and ablated, and then the AtriCure®
Lumitip Dissector was used to encircle the pulmonary
venous hilum and to guide the AtriCure® Synergy Bipo-
lar RF Clamp around the veins. Three separate lines of
ablations were performed with each being repeated
twice. Bidirectional block was then confirmed with the
pen at each location. An opening was created between
the superior vena cava and venous hilum. Working
through the transverse sinus, the right-sided portion of
the LA dome lesion was created with the AtriCure®
Coolrail linear pen. This lesion was repeated twice.
Working through the oblique sinus, the right-sided por-
tion of the LA floor lesion was created, and this lesion
was repeated twice as well. A superior vena cava lesion
is created well above the area of the sinus node with a
single application of the radiofrequency clamp. On the
left side, the autonomic ganglia and veins were treated
identically, and the dome and floor lesions were com-
pleted. Bidirectional block was confirmed for the both
veins and the box. Autonomic ganglia were localized in
the anterior and posterior fat pads, by their response to
high-frequency stimulation. Successful ganglion ablation
was defined by abolition of the heart rate response
(≥50% increase in R-R interval) to high-frequency stimu-
lation at the same regions that had elicited clear re-
sponses before ablation. Coolrail® device was then used
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to perform the LA appendage connecting lesion, which
consisted of a line on the posterior surface of the LA ap-
pendage and several stamping lesions over the base of
the LA appendage in the coumadin ridge area. Finally,
the LA appendage was excluded with AtriClip® with the
aid of transesophageal imaging to confirm a residual of
less than 1 cm at the base. Bidirectional block was then
confirmed on the LA appendage. The pericardium was
then reapproximated, and a chest tube placed. Chest
tubes were typically pulled later the day of the proced-
ure. Patients were discharged from the hospital, the day
following the procedure, unless a complication occurred.
All patients received an implantable loop recorder (ILR),
30 days post-operatively. Antiarrhythmic and anticoagu-
lation therapy were discontinued at 90 and 180 days
postoperatively, respectively, if patients were free of AF
recurrence. Failure was defined as 2 min or more, of
continuous AF or flutter on any ILR download. Proced-
ural complications were defined as major when prolong-
ing or causing a hospital admission within 30 days.
Statistical analysis
Continuous data are reported as mean ± standard deviation,
and categoric data are reported as number of subjects and
ratios. The differences between the groups were compared
using the independent-samples Student’s t-test. Chi-square
statistics were used to compare categorical variables be-
tween groups. Cox-proportional hazard survival analysis
was also conducted. Variables were entered in the model if
their univariate test p-value was ≤0.2. Statistical analysis
was conducted using MedCalc Statistical Software version
16.4.3 (MedCalc Software, Ostend, Belgium; https://www.
medcalc.org; 2016).
Results
Fifty-five patients underwent TELA during the study
period. Seven (12.5%) had previous catheter ablation
procedures before the index procedure. Baseline patient
demographics, comorbidities, and echocardiographic
characteristics are included in Table 1. The mean age of
patients was 61.6 +/− 10.7 years. Forty-four (80%) were
Table 1 Baseline demographics, clinical characteristics, and echocardiographic values
All (n = 55) No recurrence (n = 36) Recurrence (n = 19) P-value HR 95% CI
Demographics
Age 61.6 +/− 10.7 60.0 +/− 11.6 64.9 +/11.6 0.104 1.02 0.99–1.07
Males 44 (80.0%) 26 (72.2%) 18 (94.7%) 0.722 0.82 0.27–2.48
Duration in AF (years) 3.6 +/− 3.4 3.5 +/− 3.5 3.4 +/− 3.0 0.513 1.35 0.84–1.53
CHA2DS2-VASc Score 2.0 +/− 1.6 1.9 +/− 1.5 2.2 +/− 1.7 0.89 0.98 0.73–1.3
Comorbidities
Hypertension 32 (58.2%) 17 (47.2%) 15 (78.9%) 0.187 1.69 0.64–4.46
Hyperlipidemia 26 (47.3%) 13 (36.1%) 13 (68.4%) 0.686 1.2 0.49–2.97
Obstructive sleep apnea 5 (9.1%) 2 (5.6%) 3 (15.8%) 0.035 3.34 1.09–10.28
Coronary artery disease 7 (12.7%) 3 (8.3%) 4 (21.1%) 0.745 0.81 0.24–2.81
Cerebrovascular disease 0 0 0
Diabetes mellitus 6 (10.9%) 4 (11.1%) 2 (10.6%) 0.981 1.02 0.23–4.42
Echocardiographic values
Ejection Fraction (%) 61.8 +/− 5.6 61.0 +/− 6.2 62.2 +/− 4.3 0.506 1.03 0.94–1.19
Mitral regurgitation 4.01 0.93–20.57
Mild 35 (63.6%) 17 (47.2%) 17 (89.5%) 0.056
Moderate or severe 0 0 0
Tricuspid regurgitation 1.81 0.51–6.46
Mild 30 (54.5%) 18 (50.0%) 12 (63.3%) 0.99
Moderate 1 (1.8%) 0 1 (5.3%) 0.57
RA dilation 1.52 0.48–4.83
Mild 10 (18.2%) 5 (9.1%) 5 (26.3%) 0.484
Moderate 2 (3.6%) 0 2 (10.5%) 0.180
LA diameter (cm) 4.0 +/− 0.6 3.9 +/− 0.6 4.0 +/− 0.5 0.296 1.74 0.79–5.01
LA volume index (cm/m2) 29.3 +/− 8.0 27.4 +/− 5.8 31.1 +/− 9.4 0.374 1.56 0.42–5.93
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men. The mean duration in AF was 3.6 +/− 3.4 years and
the mean CHA2DS2-VASc Score was 2.0 +/− 1.6. None
of the patients had severe valvular disease. The mean left
atrial volume index was 29.3 +/− 8 mL/m2. The mean
follow-up period was 36.8 +/− 21months. Figure 1
shows a graphical representation of the percentage of
patients receiving oral anticoagulation and/or antiar-
rhythmic medications at different time points. Success
rates were 89.1% (n = 49/55), 85.5% (n = 47/55) and
76.9% (n = 40/52) at 6, 12 and 24 months, respectively.
In the multivariate cox-proportional hazard model, sur-
vival at the mean of covariates was 88, 86 and 74% at 6,
12 and 24months, respectively (Fig. 2). None of the pa-
tients in our study experienced cerebrovascular acci-
dents during follow up.
The procedure was attempted in 57 patients and com-
pleted successfully in 55 (96.5%) patients. One patient
experienced tension pneumothorax and the other expe-
rienced a major bleed during TELA and those two pa-
tients were converted to a full sternotomy for AF
ablation. Two patients experienced a minor pulmonary
vein bleed that was managed conservatively. Post pro-
cedure, one patient experienced pulmonary edema, an-
other experienced a pneumothorax requiring a chest
tube and another experienced acute respiratory distress
syndrome resulting in longer hospitalization. Otherwise,
there were no procedural complications, including
phrenic nerve injury, esophageal fistula, major bleeding,
hemothorax, cardiovascular or cerebrovascular events.
At the end of the follow up period, none of the patients
experienced any cerebrovascular accidents.
Discussion
This study investigated the long-term efficacy and safety
of TELA as a stand-alone procedure in paroxysmal AF
patients, using ILR for follow up. The major finding of
our study is that the efficacy of TELA was similar to pre-
viously published studies using catheter-based PVI.
n a metanalysis of 19 studies, the pooled 12-month suc-
cess rate for the 11 studies reporting outcomes for parox-
ysmal AF patients was 66.6% (95% CI 58.2 to 74.2%).
Single-procedure freedom from atrial arrhythmia at long-
term follow-up was 54.1% (95% CI 44.4 to 63.4%) in par-
oxysmal AF patients. The multiple-procedure long-term
success in paroxysmal AF was 79.0% in 8 studies (95% CI
67.6 to 87.1%) [9].
The efficacy results of our study are similar to previous
TELA studies. There is a limited number of publications
which reported the long-term efficacy of TELA as a
stand-alone procedure for restoration of sinus rhythm in
AF patients, likely because it was first described -only- a
little more than a decade ago. Edgerton et al. reported
the results of a prospective, nonrandomized study of 52
consecutive patients with symptomatic paroxysmal AF
undergoing TELA [6]. Unlike our study where all pa-
tients received an ILR, monitoring was obtained by ei-
ther a 24-h Holter monitor, 2- to 3-week event
monitoring, or interrogation of an implanted pacemaker.
Freedom from AF/flutter/tachycardia was 86.3 and
80.8% at 6 months and 1 year, respectively. The FAST
trial randomly assigned 124 patients with antiarrhythmic
drug-refractory AF with LA dilatation and hypertension
(33%) or failed prior catheter ablation (67%) to either
Fig. 1 Graphical representation of the percentage of patients on oral anticoagulation (Blue) and antiarrhythmic drugs (Orange) over time (in
months), following TELA
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minimally invasive surgical ablation or catheter ablation.
At 12 months, the primary end point of freedom from
LA arrhythmia of greater than 30 s without antiarrhyth-
mic drugs was significantly higher in the surgical abla-
tion group (65.6 versus 36.5%). However, there were
significantly more periprocedural complications such as
pneumothorax, major bleeding, and the need for pace-
maker in the surgical ablation group (35.4 versus 15.9%)
[8]. Rosati et al., reported the results of biatrial ablation
in 49 consecutive patients with AF who underwent
right-sided monolateral thoracoscopic ablation. Twenty-
four hours ECG Holter monitoring was used as the pri-
mary means of defining AF recurrences. At 13 months,
43 patients (87.7%) of patients were in sinus rhythm; 35
(71.4%) were free from antiarrhythmic drugs and 37
(75.5%) from oral anticoagulation [12].
None of the patients in our study experienced cerebro-
vascular accidents during follow up. With an average
CHA2DS2VASc score of 2, the estimated stroke risk for
our population would be 2.2% per year and 2.9% com-
bined risk of stroke, transient ischemic attacks or sys-
temic embolization [13, 14]. The novelty of this study
comes from exclusively studying paroxysmal AF patients
with a longer follow up period than the previous reports.
Also, all patients received an ILR, which can identify AF
recurrences when they are very infrequent [15].
Limitations
Limitations of this study include all the inherent limita-
tions of a retrospective study, and the absence of a con-
trol group. The Heart Rhythm Society defines failure
following an ablation procedure as more than 30 s of AF
and this study used a cutoff of 2 min which is the lowest
reported by an ILR. Also, there were no postprocedural
studies conducted to assess the restoration of atrial
mechanical function, in this cohort.
Conclusions
In this retrospective single center experience, TELA was
a safe and efficacious procedure for patients with parox-
ysmal AF. Long-term outcomes are similar to the gold
standard of catheter-based PVI. Results need to be vali-
dated in a randomized clinical trial fashion to compare
the safety, efficacy and quality of life metrics between
patients with atrial fibrillation undergoing thoracoscopic
epicardial versus catheter-based ablation procedures.
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